Myriad Genetics buy The Goldman Sachs Group, Inc.
Start price
23.05.23
/
50%
€21.20
Target price
23.05.24
€23.22
Performance (%)
-12.74%
Price
06.05.24
€18.50
Summary
This prediction is currently active. The price of Myriad Genetics has decreased since the start of the prediction. Compared to the start price this results in a performance of -12.74%. This prediction currently runs until 23.05.24. The prediction end date can be changed by The_Goldman_Sachs_Gr at any time. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Myriad Genetics | 10.778% | 10.778% |
iShares Core DAX® | 0.476% | -0.039% |
iShares Nasdaq 100 | 1.290% | 0.504% |
iShares Nikkei 225® | 1.300% | -2.135% |
iShares S&P 500 | 0.829% | 0.193% |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Myriad Genetics diskutieren
Myriad Genetics, Inc. (NASDAQ: MYGN) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "sell" rating to a "buy" rating. They now have a $25.00 price target on the stock, up previously from $18.00.
Ratings data for MYGN provided by MarketBeat